OBJECTIVE: The purpose was to examine in mice the efficacy of various polymeric-encapsulated C5a peptidase vaccine formulations in eliciting a long-term immune response and preventing group B streptococcus (GBS) infection. STUDY DESIGN: C5a peptidase was encapsulated in semipermeable microspheres of poly(lactide-coglycolide) (PLGA). Female ICR mice were immunized with 0, 10, or 30 μg of encapsulated C5a peptidase within 2 different formulations of PLGA polymers. Booster doses were given at weeks 4 and 8. Antibody responses were measured by enzyme-linked immunosorbent assay at weeks 4, 8, 11, and 40. Vaginal challenges with GBS types 1a, III, and V were performed at week 12. RESULTS: Thirty microgram doses of the 75:25 and 50:50 PLGA formulations generate the highest and most sustained C5a peptidase-specific immune responses. Mice that received encapsulated C5a peptidase were significantly protected from vaginal colonization compared with mice that received empty microspheres. CONCLUSION: Encapsulated C5a peptidase elicited significant immune responses and protection against a GBS challenge. C5a peptidase microsphere encapsulation has potential as a GBS vaccine.
OBJECTIVE: The purpose was to examine in mice the efficacy of various polymeric-encapsulated C5a peptidase vaccine formulations in eliciting a long-term immune response and preventing group B streptococcus (GBS) infection. STUDY DESIGN: C5a peptidase was encapsulated in semipermeable microspheres of poly(lactide-coglycolide) (PLGA). Female ICR mice were immunized with 0, 10, or 30 μg of encapsulated C5a peptidase within 2 different formulations of PLGA polymers. Booster doses were given at weeks 4 and 8. Antibody responses were measured by enzyme-linked immunosorbent assay at weeks 4, 8, 11, and 40. Vaginal challenges with GBS types 1a, III, and V were performed at week 12. RESULTS: Thirty microgram doses of the 75:25 and 50:50 PLGA formulations generate the highest and most sustained C5a peptidase-specific immune responses. Mice that received encapsulated C5a peptidase were significantly protected from vaginal colonization compared with mice that received empty microspheres. CONCLUSION: Encapsulated C5a peptidase elicited significant immune responses and protection against a GBS challenge. C5a peptidase microsphere encapsulation has potential as a GBS vaccine.
Authors: C Kent Brown; Zu-Yi Gu; Yury V Matsuka; Sai S Purushothaman; Laurie A Winter; P Patrick Cleary; Stephen B Olmsted; Douglas H Ohlendorf; Cathleen A Earhart Journal: Proc Natl Acad Sci U S A Date: 2005-12-12 Impact factor: 11.205
Authors: Jacqueline A Baker; Emma L Lewis; Leah M Byland; Maryam Bonakdar; Tara M Randis; Adam J Ratner Journal: Vaccine Date: 2017-02-02 Impact factor: 3.641
Authors: Thomas A Hooven; Andrew J Catomeris; Leor H Akabas; Tara M Randis; Duncan J Maskell; Sarah E Peters; Sandra Ott; Ivette Santana-Cruz; Luke J Tallon; Hervé Tettelin; Adam J Ratner Journal: BMC Genomics Date: 2016-05-26 Impact factor: 3.969
Authors: T Gupalova; G Leontieva; T Kramskaya; K Grabovskaya; E Bormotova; D Korjevski; A Suvorov Journal: PLoS One Date: 2018-05-04 Impact factor: 3.240